{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:10:37Z","timestamp":1763017837049,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.phrs.2018.02.010","type":"journal-article","created":{"date-parts":[[2018,2,11]],"date-time":"2018-02-11T10:15:58Z","timestamp":1518344158000},"page":"218-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Detection of drug safety signals from clinical trials data: Role of SUSARs"],"prefix":"10.1016","volume":"131","author":[{"given":"Christelle","family":"Perez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Lortal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Duranton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Laur\u00e8ne","family":"Colin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Toulza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madlyne","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Hamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Crepin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Roussillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Gimbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Petitpain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.phrs.2018.02.010_bib0005","first-page":"12","volume":"9","year":"2002","journal-title":"Med Etika Bioet"},{"issue":"4","key":"10.1016\/j.phrs.2018.02.010_bib0010","first-page":"317","article-title":"Regulation (EU) No 536\/2014 on clinical trials on medicinal products for human use: an overview","volume":"50","author":"Petrini","year":"2014","journal-title":"Ann. Ist. Super. Sanita"},{"issue":"2","key":"10.1016\/j.phrs.2018.02.010_bib0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00002018-200932020-00003","article-title":"Defining \u2018signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions","volume":"32","author":"Hauben","year":"2009","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.phrs.2018.02.010_bib0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.phrs.2018.02.010_bib0025","unstructured":"Food, H.H.S. Drug Administration, International Conference on Harmonisation; Electronic Transmission of Postmarket Individual Case Safety Reports for Drugs and Biologics, Excluding Vaccines; Availability of Food and Drug Administration Regional Implementation Specifications for ICH E2B(R3) Reporting to the Food and Drug Administration Adverse Event Reporting System. Notice of Availability, Fed Regist 81(121) (2016) 40890-1."},{"issue":"2","key":"10.1016\/j.phrs.2018.02.010_bib0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salame","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.phrs.2018.02.010_bib0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.phrs.2017.07.005","article-title":"Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting","volume":"123","author":"Mascolo","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.phrs.2018.02.010_bib0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0755-4982(05)83904-1","article-title":"[Medical and socio-economical impact of drug-induced adverse reactions]","volume":"34","author":"Apretna","year":"2005","journal-title":"Presse Med."},{"issue":"20","key":"10.1016\/j.phrs.2018.02.010_bib0045","first-page":"1","article-title":"Evaluation of patient reporting of adverse drug reactions to the UK \u2018Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys","volume":"15","author":"Avery","year":"2011","journal-title":"Health technology assessment (Winchester, England)"},{"issue":"1","key":"10.1016\/j.phrs.2018.02.010_bib0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1586\/17512433.2015.974555","article-title":"Adverse reactions to oncologic drugs: spontaneous reporting and signal detection","volume":"8","author":"Tuccori","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.phrs.2018.02.010_bib0055","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/00002018-200528080-00007","article-title":"Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986\u20132001)","volume":"28","author":"Thiessard","year":"2005","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.phrs.2018.02.010_bib0060","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1472-8206.2002.00100.x","article-title":"Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France","volume":"16","author":"Montastruc","year":"2002","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2018.02.010_bib0065","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pds.4155","article-title":"Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden","volume":"26","author":"Holm","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"3\u20134","key":"10.1016\/j.phrs.2018.02.010_bib0070","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2008.07.003","article-title":"Allergic reactions to oral drugs: a case\/non-case study from an Italian spontaneous reporting database (GIF)","volume":"58","author":"Salvo","year":"2008","journal-title":"Pharmacol. Res."},{"issue":"7299","key":"10.1016\/j.phrs.2018.02.010_bib0075","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/465688a","article-title":"Sex bias in trials and treatment must end","volume":"465","author":"Kim","year":"2010","journal-title":"Nature"},{"issue":"7674","key":"10.1016\/j.phrs.2018.02.010_bib0080","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/550S18a","article-title":"Clinical research: inequality in medicine","volume":"550","author":"Nowogrodzki","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.phrs.2018.02.010_bib0085","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","article-title":"Adverse drug reaction reporting in africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase(R)","volume":"39","author":"Ampadu","year":"2016","journal-title":"Drug Saf."},{"issue":"12","key":"10.1016\/j.phrs.2018.02.010_bib0090","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/BF03262002","article-title":"Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase","volume":"35","author":"Aagaard","year":"2012","journal-title":"Drug Saf."},{"issue":"3","key":"10.1016\/j.phrs.2018.02.010_bib0095","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.phrs.2006.05.003","article-title":"Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital","volume":"54","author":"Jose","year":"2006","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.02.010_bib0100","unstructured":"LEEM, French attractiveness for international clinical research \u2013 2016 Leem survey (eight edition). http:\/\/www.leem.org\/sites\/default\/files\/LEEM-Enque%CC%82te-2016_synthe%CC%80se%20VF%20-%20152%20Mo.pdf."},{"issue":"4","key":"10.1016\/j.phrs.2018.02.010_bib0105","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/bcp.13035","article-title":"Serious adverse drug events related to non-investigational drugs in academic clinical trials: another source of safety data for risk assessment?","volume":"82","author":"Olivier","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.02.010_bib0110","unstructured":"EMA, Good pharmacovigilance practices. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/document_listing\/document_listing_000345.jsp. (Accessed 11 September 2017)."},{"issue":"23","key":"10.1016\/j.phrs.2018.02.010_bib0115","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMe1705439","article-title":"Data sharing statements for clinical trials \u2212 a requirement of the international committee of medical journal editors","volume":"376","author":"Taichman","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.phrs.2018.02.010_bib0120","first-page":"830","article-title":"Assessment of serious adverse events in academic clinical trials: Concordance between investigator and sponsor","volume":"36","author":"Bezin","year":"2018","journal-title":"Drug Saf."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817316316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817316316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:57:39Z","timestamp":1760911059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817316316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":24,"alternative-id":["S1043661817316316"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.02.010","relation":{},"ISSN":["1043-6618"],"issn-type":[{"type":"print","value":"1043-6618"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of drug safety signals from clinical trials data: Role of SUSARs","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}